Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mast cells as a therapeutic target in myeloproliferative neoplasms.

Trends in molecular medicine - 1 Nov 2022

Toledo Marcelo A S, Chatain Nicolas, Zenke Martin, Koschmieder Steffen

Abstract excerpt

Mast cells have been implicated as mediators of bone marrow fibrosis and pruritus in myeloproliferative neoplasms (MPNs) with JAK2V617F or calreticulin mutations. We hypothesize that potent KIT inhibitors, already in clinical use for systemic mastocytosis, have therapeutic potential for the treatment of MPNs by directly targeting mast cells.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mast Cells
Share to Mastocytosis, Systemic
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Source

Identifiers

PMID: 36064534
DOI: 10.1016/j.molmed.2022.08.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mast cells as a therapeutic target in myeloproliferative neoplasms.PMID 36064534Read ↗

Recent advances in the understanding and therapeutic management of mastocytosisSemantic proximity Read ↗

Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.Semantic proximity Read ↗

Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy.Semantic proximity Read ↗

Mastocytosis: from a Molecular Point of View.Semantic proximity Read ↗

Mastocytosis.Semantic proximity Read ↗

On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.Semantic proximity Read ↗

Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.Semantic proximity Read ↗

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.Semantic proximity Read ↗

Mastocytosis: state of the art.Semantic proximity Read ↗

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.Semantic proximity Read ↗

Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine conceptsSemantic proximity Read ↗

Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.